ReSPECT™ Clinical Trials
  • LEPTOMENINGEAL METASTASES (LM)
    • CANCER GUIDE FOR PATIENTS
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
      • RESOURCES
    • CLINICAL TRIAL
      • TRIAL INFORMATION
      • PATIENT ELIGIBILITY
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • CONTACT US
      • NEXT STEPS
      • NEWS
      • PUBLICATIONS
      • RESOURCES
  • RECURRENT GLIOBLASTOMA (GBM)
    • CANCER GUIDE FOR PATIENTS
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
      • RESOURCES
    • CLINCIAL TRIAL
      • TRIAL INFORMATION
        • QUICK OVERVIEW
      • TRIAL GUIDE FOR PATIENTS
      • PATIENT ELIGIBILITY
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • NEXT STEPS
      • CONTACT US
      • NEWS
      • PUBLICATIONS
      • RESOURCES
  • PEDIATRIC BRAIN CANCER
    • CANCER GUIDE FOR PATIENTS- EPENDYMOMA
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
    • CANCER GUIDE FOR PATIENTS – HIGH GRADE GLIOMA
      • DISEASE BACKGROUND
      • DIAGNOSIS
      • TREATMENT OPTIONS
    • CLINICAL TRIAL
      • TRIAL INFORMATION
      • PRINCIPAL INVESTIGATORS
      • TRIAL LOCATIONS
      • NEXT STEPS
      • NEWS
      • PUBLICATIONS
      • RESOURCES
Select Page

Plus Therapeutics Joins the 7th Annual Head for the Cure 5K in Phoenix

by Plus Therapeutics | Oct 27, 2025 | Uncategorized

Last weekend, members of the Plus Therapeutics team — led by Gabby Cleveland — participated in the 7th Annual Head for the Cure Foundation 5K in Phoenix, Arizona, standing alongside patients, caregivers, and advocates united in the fight against brain cancer. This...

Insights from Plus Therapeutics’ CEO Featured in Nature Cancer

by Plus Therapeutics | Oct 23, 2025 | Uncategorized

Plus Therapeutics’ President & CEO, Marc Hedrick, M.D., was recently featured as a key opinion leader in a Nature Cancer article by Melanie Senior highlighting how biotechnology companies are advancing the next generation of radiopharmaceutical therapies ahead of...

ReSPECT Team Supports Cancer Research at the Winship 5K During Breast Cancer Awareness Month

by Plus Therapeutics | Oct 6, 2025 | Uncategorized

This past weekend, Plus Therapeutics’ Andrew Sims and Conroy Campbell proudly participated in the Winship 5K, supporting the Winship Cancer Institute of Emory University and its mission to advance lifesaving cancer research. The annual Winship 5K unites cancer...

Targeted Radiotherapies and Brain Tumor Treatment Challenges on The Bio Report Podcast

by Plus Therapeutics | Sep 15, 2025 | Uncategorized

Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics (Nasdaq: PSTV), recently joined Daniel Levine, host of The Bio Report podcast by Levine Media Group, to discuss the challenges of treating brain tumors, the limitations of current...

Plus Therapeutics CEO Highlights the Role of Precision Medicine in Cancer Treatment

by Plus Therapeutics | Sep 8, 2025 | Uncategorized

Marc Hedrick, M.D., President and CEO of Plus Therapeutics (NASDAQ: PSTV), was recently featured in Pharma’s Almanac, where he shared insights on how precision medicine is reshaping the future of oncology. Precision Medicine in Cancer Care In the article, Dr. Hedrick...

Transforming Radiation Therapy: Q&A with Plus Therapeutics CEO Dr. Marc Hedrick

by Plus Therapeutics | Jul 30, 2025 | Uncategorized

In a recent interview with Drug Development & Delivery, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, shared insights into the company’s innovative approach to treating central nervous system (CNS) and solid tumor cancers using targeted...
« Older Entries
Next Entries »

Recent Posts

  • AJMC: Leptomeningeal Metastases Data at SABCS 2025
  • Targeted Radiotherapeutics: A New Generation of Precision Cancer Treatment
  • ReSPECT-LM Clinical Trial Highlights Phase 1 Results at SABCS 2025
  • Three Positive Clinical Data Updates at WFNOS / SNO 2025 Annual Meeting
  • Progress, Potential, and Possibilities Podcast

Recent Comments

    • Expanded Access Policy
    • Privacy Policy
    • Terms of Use
    • Forward Looking Statement
    • Social Media Guidelines
    • ReSPECT Blog
    Copyright © 2025 Plus Therapeutics, Inc. All rights reserved. ReSPECT is a trademark of Plus Therapeutics, Inc. This website is intended for a U.S. audience only.
    This site uses cookies to improve your experience. A cookie is a file sent to your device when you access a site. By using this site, you agree to the use of cookies on your device for tracking and analytics. Cookie SettingsACCEPT
    Privacy & Cookies Policy

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
    Non-necessary
    Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
    SAVE & ACCEPT